Literature DB >> 30179645

Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care.

Kate Nambiar1, Harald Seifert2, Siegbert Rieg3, Winfried V Kern3, Matt Scarborough4, N Claire Gordon4, Hong Bin Kim5, Kyoung-Ho Song5, Robert Tilley6, Hannah Gott7, Chun-Hsing Liao8, Jonathan Edgeworth9, Emmanuel Nsutebu10, Luis Eduardo López-Cortés11, Laura Morata12, A Sarah Walker13, Guy Thwaites14, Martin J Llewelyn1, Achim J Kaasch15.   

Abstract

BACKGROUND: Staphylococcus aureus bloodstream infection (SAB) is a common, life-threatening infection with a high mortality. Survival can be improved by implementing quality of care bundles in hospitals. We previously observed marked differences in mortality between hospitals and now assessed whether mortality could serve as a valid and easy to implement quality of care outcome measure.
METHODS: We conducted a prospective observational study between January 2013 and April 2015 on consecutive, adult patients with SAB from 11 tertiary care centers in Germany, South Korea, Spain, Taiwan, and the United Kingdom. Factors associated with mortality at 90 days were analyzed by Cox proportional hazards regression and flexible parametric models.
RESULTS: 1851 patients with a median age of 66 years (64% male) were analyzed. Crude 90-day mortality differed significantly between hospitals (range 23-39%). Significant variation between centers was observed for methicillin-resistant S. aureus, community-acquisition, infective foci, as well as measures of comorbidities, and severity of disease. In multivariable analysis, factors independently associated with mortality at 90 days were age, nosocomial acquisition, unknown infective focus, pneumonia, Charlson comorbidity index, SOFA score, and study center. The risk of death varied over time differently for each infective focus. Crude mortality differed markedly from adjusted mortality. DISCUSSION: We observed significant differences in adjusted mortality between hospitals, suggesting differences in quality of care. However, mortality is strongly influenced by patient mix and thus, crude mortality is not a suitable quality indicator.
Copyright © 2018 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteremia; Mortality; Observational study; Quality measures; Staphylococcus aureus

Mesh:

Substances:

Year:  2018        PMID: 30179645     DOI: 10.1016/j.jinf.2018.08.015

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  10 in total

1.  Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections.

Authors:  Yeon Ju La; Hye Rim Kim; Dong Hyun Oh; Jin Young Ahn; Yong Chan Kim
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

2.  Comparable Effectiveness of Cefuroxime and Piperacillin-Tazobactam as Empirical Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia.

Authors:  Robert Strengen Bigseth; Håkon Sandholdt; Andreas Petersen; Christian Østergaard; Thomas Benfield; Louise Thorlacius-Ussing
Journal:  Microbiol Spectr       Date:  2022-04-19

3.  Genomic Surveillance of Methicillin-resistant Staphylococcus aureus: A Mathematical Early Modeling Study of Cost-effectiveness.

Authors:  Amy Dymond; Heather Davies; Stuart Mealing; Vicki Pollit; Francesc Coll; Nicholas M Brown; Sharon J Peacock
Journal:  Clin Infect Dis       Date:  2020-04-10       Impact factor: 9.079

4.  Effect of Clinically Uninfected Orthopedic Implants and Pacemakers/AICDs in Low-Risk Staphylococcus aureus Bloodstream Infection on Crude Mortality Rate: A Post Hoc Analysis of a Large Cohort Study.

Authors:  Achim J Kaasch; Winfried V Kern; Insa Joost; Martin Hellmich; Harald Seifert; Siegbert Rieg
Journal:  Open Forum Infect Dis       Date:  2019-04-15       Impact factor: 3.835

5.  Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection.

Authors:  Achim J Kaasch; Anna Rommerskirchen; Martin Hellmich; Gerd Fätkenheuer; Reinhild Prinz-Langenohl; Siegbert Rieg; Winfried V Kern; Harald Seifert
Journal:  Trials       Date:  2020-02-12       Impact factor: 2.279

6.  Development of quality indicators for the management of Staphylococcus aureus bacteraemia.

Authors:  Jaap Ten Oever; Joëll L Jansen; Thomas W van der Vaart; Jeroen A Schouten; Marlies E J L Hulscher; Annelies Verbon
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

Review 7.  Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.

Authors:  Lloyd S Miller; Vance G Fowler; Sanjay K Shukla; Warren E Rose; Richard A Proctor
Journal:  FEMS Microbiol Rev       Date:  2020-01-01       Impact factor: 16.408

8.  Clinical Characteristics and Outcomes of S. Aureus Bacteremia in Patients Receiving Total Parenteral Nutrition.

Authors:  Michelle Gompelman; Renée A M Tuinte; Marvin A H Berrevoets; Chantal P Bleeker-Rovers; Geert J A Wanten
Journal:  Nutrients       Date:  2020-10-14       Impact factor: 5.717

9.  Antimicrobial resistance determinants are associated with Staphylococcus aureus bacteraemia and adaptation to the healthcare environment: a bacterial genome-wide association study.

Authors:  Bernadette C Young; Chieh-Hsi Wu; Jane Charlesworth; Sarah Earle; James R Price; N Claire Gordon; Kevin Cole; Laura Dunn; Elian Liu; Sarah Oakley; Heather Godwin; Rowena Fung; Ruth Miller; Kyle Knox; Antonina Votintseva; T Phuong Quan; Robert Tilley; Matthew Scarborough; Derrick W Crook; Timothy E Peto; A Sarah Walker; Martin J Llewelyn; Daniel J Wilson
Journal:  Microb Genom       Date:  2021-11

10.  Genome Evolution of Invasive Methicillin-Resistant Staphylococcus aureus in the Americas.

Authors:  Joshua T Smith; Elissa M Eckhardt; Nicole B Hansel; Tahmineh Rahmani Eliato; Isabella W Martin; Cheryl P Andam
Journal:  Microbiol Spectr       Date:  2022-05-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.